Developing biologics for medical conditions where there has been no approved or satisfactory therapy.
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnova.... |
| - | Life Scien... | lspvc.com |
Mentions in press and media 7
| Date | Title | Description | Category | Author | Source |
| - | Rainier Th... | -Targeted antibody elicits res... | - | - | healthcap.... |
| - | Rainier Th... | -FIERCE-21 and FIERCE-22 Phase... | - | - | healthcap.... |
| - | Rainier Th... | SAN LEANDRO, Calif., May 1, 20... | - | - | healthcap.... |
| - | BioClin Th... | SAN LEANDRO, Calif., November ... | - | - | healthcap.... |
| - | Rainier Th... | – Updated Interim Analysis fro... | - | - | healthcap.... |
| - | Rainier Th... | – Vofatamab activates immune c... | - | - | healthcap.... |
| - | Rainier Th... | – Preliminary data from FIERCE... | - | - | healthcap.... |